JP2019504068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504068A5 JP2019504068A5 JP2018535888A JP2018535888A JP2019504068A5 JP 2019504068 A5 JP2019504068 A5 JP 2019504068A5 JP 2018535888 A JP2018535888 A JP 2018535888A JP 2018535888 A JP2018535888 A JP 2018535888A JP 2019504068 A5 JP2019504068 A5 JP 2019504068A5
- Authority
- JP
- Japan
- Prior art keywords
- domperidone
- gastroparesis
- compound
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001253 domperidone Drugs 0.000 claims description 16
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 11
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 8
- 208000001288 gastroparesis Diseases 0.000 claims description 8
- 206010028813 Nausea Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 230000006651 lactation Effects 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 230000008673 vomiting Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 description 4
- 108050004812 Dopamine receptor Proteins 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000030135 gastric motility Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291198P | 2016-02-04 | 2016-02-04 | |
| US62/291,198 | 2016-02-04 | ||
| PCT/US2017/016334 WO2017136617A1 (en) | 2016-02-04 | 2017-02-03 | Deuterated domperidone compositions and methods for therapy of disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504068A JP2019504068A (ja) | 2019-02-14 |
| JP2019504068A5 true JP2019504068A5 (enExample) | 2020-03-12 |
| JP7296185B2 JP7296185B2 (ja) | 2023-06-22 |
Family
ID=59501077
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535888A Active JP7296185B2 (ja) | 2016-02-04 | 2017-02-03 | 重水素化ドンペリドン組成物及び疾患の治療方法 |
| JP2019571517A Active JP7602324B2 (ja) | 2016-02-04 | 2018-06-28 | 重水素化ドンペリドン組成物、方法、及び調製 |
| JP2022205876A Pending JP2023052045A (ja) | 2016-02-04 | 2022-12-22 | 重水素化ドンペリドン組成物、方法、及び調製 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571517A Active JP7602324B2 (ja) | 2016-02-04 | 2018-06-28 | 重水素化ドンペリドン組成物、方法、及び調製 |
| JP2022205876A Pending JP2023052045A (ja) | 2016-02-04 | 2022-12-22 | 重水素化ドンペリドン組成物、方法、及び調製 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10266516B2 (enExample) |
| EP (2) | EP3411031B1 (enExample) |
| JP (3) | JP7296185B2 (enExample) |
| KR (2) | KR102851614B1 (enExample) |
| CN (4) | CN108697700B (enExample) |
| AU (2) | AU2017213852B2 (enExample) |
| BR (2) | BR112018016032B1 (enExample) |
| CA (2) | CA3013123A1 (enExample) |
| DK (2) | DK3411031T3 (enExample) |
| EA (2) | EA035515B1 (enExample) |
| WO (2) | WO2017136617A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| DK3411031T3 (da) | 2016-02-04 | 2024-10-21 | Cindome Pharma Inc | Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| KR20240125702A (ko) | 2017-06-30 | 2024-08-19 | 신돔 파마, 인크. | 중수소화 돔페리돈 조성물, 방법, 및 제조 |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| AU2019290231A1 (en) * | 2018-06-21 | 2020-12-17 | Dermavant Sciences GmbH | Topical formulations of DGAT1 inhibitors and their methods of use |
| KR20210082480A (ko) * | 2018-10-25 | 2021-07-05 | 신돔 파마, 인크. | 돔페리돈을 함유하는 제제 |
| AU2019366993B2 (en) * | 2018-10-25 | 2024-02-15 | Cindome Pharma, Inc. | Formulations containing deuterated domperidone |
| US20220307004A1 (en) * | 2021-03-29 | 2022-09-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Multi-Enzyme Nanoparticle-Assisted Stable Isotope Incorporation Into Small Molecules by Channeling |
| CN119300829A (zh) * | 2022-04-20 | 2025-01-10 | 辛多美制药有限公司 | 用于治疗胃轻瘫的氘代多潘立酮 |
| AU2024238849A1 (en) * | 2023-03-23 | 2025-09-18 | Cindome Pharma, Inc. | Methods for treating diabetic gastroparesis |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4066772A (en) | 1975-07-21 | 1978-01-03 | Janssen Pharmaceutica N.V. | 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds |
| NZ181256A (en) * | 1975-07-21 | 1978-04-28 | Janssen Pharmaceutica Nv | 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives |
| TW466119B (en) * | 1994-02-28 | 2001-12-01 | Janssen Pharmaceutica Nv | Film coated tablet of paracetamol and domperidone |
| FR2725986B1 (fr) * | 1994-10-21 | 1996-11-29 | Adir | Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| US20130220526A1 (en) | 2001-10-12 | 2013-08-29 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
| US20140070440A1 (en) | 2001-10-12 | 2014-03-13 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
| US20140271788A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US20140163060A1 (en) | 2001-10-12 | 2014-06-12 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
| US20160206639A9 (en) | 2001-10-12 | 2016-07-21 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
| ITMI20020514A1 (it) | 2002-03-12 | 2003-09-12 | Jagotec Ag | Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi |
| US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
| ES2500316T3 (es) | 2002-10-01 | 2014-09-30 | Banner Pharmacaps, Inc. | Composición entérica para la fabricación de una cubierta de cápsula blanda |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| CA2858733C (en) | 2004-12-31 | 2017-12-19 | Iceutica Pty Ltd | Nanoparticle compositions and methods for synthesis thereof |
| ITMI20050477A1 (it) | 2005-03-23 | 2006-09-24 | Bouty S P A | Cerotto transdermico |
| CN100386323C (zh) * | 2006-02-27 | 2008-05-07 | 南京长澳医药科技有限公司 | 马来酸多潘立酮的合成方法 |
| US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| CN101568330A (zh) | 2006-06-30 | 2009-10-28 | 伊休蒂卡有限公司 | 用于制备纳米粒形式的生物活性化合物的方法 |
| MX2009011577A (es) | 2007-04-26 | 2010-03-10 | Craig A Aronchick | Composiciones y metodos para distribucion de domperidona a traves de la mucosa. |
| EP2630955B1 (en) | 2007-08-15 | 2021-09-22 | Johnson & Johnson Consumer Inc. | Immediate release and sustained release ibuprofen dosing regimen |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090076010A1 (en) | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched lamotrigine |
| WO2009146310A1 (en) | 2008-05-28 | 2009-12-03 | Concert Pharmaceuticals Inc. | Deuterated tizanidine |
| US20100113405A1 (en) * | 2008-11-06 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Methylindazole modulators of 5-ht3 receptors |
| WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| NZ595903A (en) | 2009-04-24 | 2014-03-28 | Iceutica Pty Ltd | A novel formulation of metaxalone |
| EA201171282A1 (ru) | 2009-04-24 | 2012-05-30 | Айсьютика Пти Лтд. | Способ производства коммерческих порошков, содержащих нано- и микрочастицы |
| UA111578C2 (uk) | 2009-04-24 | 2016-05-25 | Айсьютіка Пті Лтд | Спосіб одержання композиції, що містить напроксен |
| MY159208A (en) | 2009-04-24 | 2016-12-30 | Iceutica Pty Ltd | A novel formulation of indomethacin |
| AP2015008933A0 (en) | 2009-04-24 | 2015-12-31 | Iceutica Pty Ltd | A novel formulation of diclofenac |
| US20140017299A1 (en) | 2011-08-18 | 2014-01-16 | Monosol Rx, Llc | Steroid hormone delivery systems and methods of preparing the same |
| CN104136025B (zh) | 2012-02-28 | 2017-10-24 | 日绊株式会社 | 贴附剂 |
| CA2876306C (en) | 2012-06-15 | 2024-02-20 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| NZ734451A (en) * | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| US20140019395A1 (en) | 2012-07-12 | 2014-01-16 | Craig Charles Bauer | Method and application of Fear, Love and Methodology as protocols within and of a programming group, as a means of creating an artificial individual, software system or other independent entity capable of independent self directive creation of choice and/or self directive creation of purpose within a virtual and/or any environment |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| US20140271787A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Continuous single layer film structure including discrete domains |
| KR20160023641A (ko) | 2013-03-15 | 2016-03-03 | 아이슈티카 인코포레이티드 | 아비라테론 아세테이트 제제 |
| US20140272220A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Reduction in stress cracking of films |
| DK3411031T3 (da) | 2016-02-04 | 2024-10-21 | Cindome Pharma Inc | Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser |
-
2017
- 2017-02-03 DK DK17748198.3T patent/DK3411031T3/da active
- 2017-02-03 EA EA201891727A patent/EA035515B1/ru not_active IP Right Cessation
- 2017-02-03 CN CN201780008640.9A patent/CN108697700B/zh active Active
- 2017-02-03 AU AU2017213852A patent/AU2017213852B2/en active Active
- 2017-02-03 WO PCT/US2017/016334 patent/WO2017136617A1/en not_active Ceased
- 2017-02-03 CA CA3013123A patent/CA3013123A1/en active Pending
- 2017-02-03 EP EP17748198.3A patent/EP3411031B1/en active Active
- 2017-02-03 CN CN202111078948.5A patent/CN113995755A/zh active Pending
- 2017-02-03 BR BR112018016032-6A patent/BR112018016032B1/pt active IP Right Grant
- 2017-02-03 KR KR1020187023566A patent/KR102851614B1/ko active Active
- 2017-02-03 JP JP2018535888A patent/JP7296185B2/ja active Active
- 2017-06-30 US US15/639,431 patent/US10266516B2/en active Active
-
2018
- 2018-06-28 CA CA3055777A patent/CA3055777A1/en active Pending
- 2018-06-28 CN CN201880043378.6A patent/CN111093653B/zh active Active
- 2018-06-28 AU AU2018290905A patent/AU2018290905B2/en active Active
- 2018-06-28 EA EA202090183A patent/EA202090183A1/ru unknown
- 2018-06-28 DK DK18743261.2T patent/DK3644995T3/da active
- 2018-06-28 BR BR112019028185A patent/BR112019028185A8/pt not_active Application Discontinuation
- 2018-06-28 JP JP2019571517A patent/JP7602324B2/ja active Active
- 2018-06-28 CN CN202310648870.9A patent/CN116712432A/zh active Pending
- 2018-06-28 KR KR1020207002879A patent/KR102695402B1/ko active Active
- 2018-06-28 EP EP18743261.2A patent/EP3644995B1/en active Active
- 2018-06-28 WO PCT/US2018/039928 patent/WO2019006078A1/en not_active Ceased
-
2019
- 2019-04-16 US US16/385,599 patent/US10590110B2/en active Active
-
2022
- 2022-12-22 JP JP2022205876A patent/JP2023052045A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504068A5 (enExample) | ||
| Mercadante et al. | Pharmacological management of cancer pain in the elderly | |
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| JP2020500862A5 (enExample) | ||
| CY1111500T1 (el) | Οπιοειδη για τη θεραπεια χρονιας αποφρακτικης πνευμονοπαθειας (copd) | |
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| JP2009539827A5 (enExample) | ||
| RU2019142694A (ru) | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| JP2018535989A5 (enExample) | ||
| CN101073563A (zh) | 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片 | |
| CN104853755A (zh) | 包含沃替西汀和多奈哌齐的组合物 | |
| RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
| JP2016527312A (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療する方法 | |
| JP2010500284A5 (enExample) | ||
| JP2008538583A5 (enExample) | ||
| JP2019524888A5 (enExample) | ||
| JP2016529236A5 (enExample) | ||
| JP2018502089A5 (enExample) | ||
| MX391602B (es) | Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso | |
| RU2018119085A (ru) | Схема введения ингибитора фосфатидилинозитол-3-киназы | |
| WO2011080502A3 (en) | New pharmaceutical dosage form for the treatment of gastric acid-related disorders | |
| WO2015166419A2 (es) | Proceso de obtención y composición farmacéutica de ketorolaco trometamina y clorhidrato de tramadol sublingual usado para el dolor | |
| CA2576926A1 (en) | Use of midostaurin for treating gastrointestinal stromal tumors | |
| RU2003106200A (ru) | Способ анестезиологического пособия при оперативных вмешательствах |